Phase 2Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrolment
- 160 planned
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Pumitamig; Imzokitug; Pemetrexed; Cisplatin; Carboplatin; Paclitaxel
- Ages
- adults, older adults
- Registry
- NCT07680764
From the registry
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Primary outcomes
- Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)